According to the in-depth research, Treg can inhibit CD8+ effector T cells, which are the major defender to tumor, with the help of multiple functional surface molecules and inhibitory cytokines like TGF-β (transforming growth factor-β) [61, 62]. This evidence concerns the gene CD8A and neoplasm.